<DOC>
	<DOCNO>NCT02019472</DOCNO>
	<brief_summary>The primary objective investigate efficacy sirukumab monotherapy compare adalimumab monotherapy biologic na誰ve subject active rheumatoid arthritis intolerant methotrexate , consider inappropriate treatment methotrexate inadequate responder methotrexate .</brief_summary>
	<brief_title>A Study Comparing Sirukumab ( CNTO 136 ) Monotherapy With Adalimumab ( HUMIRA速 ) Monotherapy Treatment Active Rheumatoid Arthritis</brief_title>
	<detailed_description>This randomize , double-blind , parallel-group , global , multicenter study subcutaneous ( SC ) sirukumab monotherapy compare adalimumab monotherapy subject active rheumatoid arthritis . Approximately 510 subject randomly assign 1:1:1 ratio receive treatment adalimumab 40 mg SC every 2 week , sirukumab 100 mg SC every 2 week , 50 mg SC every 4 week , approximately 170 subject per treatment group . At Week 16 , subject treatment group &lt; 20 % improvement baseline swell tender joint count qualify early escape . The expected duration study 68 week . This include 52 week treatment study agent 16 week safety follow-up last study agent administration . The study end last subject completes last scheduled visit ( Week 68 visit completes 16 week safety follow-up , whichever later ) . Subject safety monitor end study .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Have diagnosis rheumatoid arthritis ( RA ) least 6 month screen Have moderately severely active RA least 8 68 tender joint 6 66 swollen joint , screen baseline Have previous current treatment methotrexate ( MTX ) consider intolerant MTX , and/or consider inappropriate treatment MTX , ( include MTXna誰ve subject inappropriate administer MTX ) and/or inadequate responder methotrexate Must receive MTX nonbiologic DMARD include limited sulfasalazine , hydroxychloroquine , chloroquine , bucillamine least 2 week prior first administration study agent Creactive protein &gt; = 10.00 mg/L erythrocyte sedimentation rate &gt; =28 mm/hr screening Has Functional Class IV define ACR Classification Functional Status Rheumatoid Arthritis Has ever receive biologic therapy RA , include limited following : TNFalpha inhibitor , tocilizumab , rituximab , anakinra , abatacept Has ever use tofacitinib therapy JAK inhibitor Has receive intraarticular , intramuscular , IV corticosteroid RA , include adrenocorticotrophic hormone 4 week prior first study agent administration Has receive leflunomide within 24 month first study agent administration undergone drug elimination procedure , unless M1 metabolite measure undetectable</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Rheumatoid arthritis</keyword>
	<keyword>CNTO 136</keyword>
	<keyword>Sirukumab</keyword>
	<keyword>Adalimumab</keyword>
	<keyword>HUMIRA速</keyword>
</DOC>